These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33668399)

  • 1. p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53.
    Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; D'Orazi G; Cirone M
    Biomolecules; 2021 Feb; 11(3):. PubMed ID: 33668399
    [No Abstract]   [Full Text] [Related]  

  • 2. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degradation of mutant p53H175 protein by Zn(II) through autophagy.
    Garufi A; Pucci D; D'Orazi V; Cirone M; Bossi G; Avantaggiati ML; D'Orazi G
    Cell Death Dis; 2014 May; 5(5):e1271. PubMed ID: 24874727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
    FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.
    Kalo E; Kogan-Sakin I; Solomon H; Bar-Nathan E; Shay M; Shetzer Y; Dekel E; Goldfinger N; Buganim Y; Stambolsky P; Goldstein I; Madar S; Rotter V
    J Cell Sci; 2012 Nov; 125(Pt 22):5578-86. PubMed ID: 22899716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies.
    D'Orazi G; Cordani M; Cirone M
    Cell Mol Life Sci; 2021 Mar; 78(5):1853-1860. PubMed ID: 33070220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer efficacy of hirsuteine against colorectal cancer by opposite modulation of wild-type and mutant p53.
    Zhang Y; Guo T; Li S; Ren Z; Gao S; Lu H; Ma X; Liu D; Liu Y; Kong D; Qiu Y
    Discov Oncol; 2023 May; 14(1):84. PubMed ID: 37256374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
    Kim E; Giese A; Deppert W
    Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
    Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
    J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells.
    Cordani M; Butera G; Pacchiana R; Masetto F; Mullappilly N; Riganti C; Donadelli M
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Δ40p53 is involved in the inactivation of autophagy and contributes to inhibition of cell death in HCT116-Δ40p53 cells.
    Zang Y; Shi Y; Liu K; Qiao L; Guo X; Chen D
    Oncotarget; 2017 Feb; 8(8):12754-12763. PubMed ID: 28061446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death.
    Granato M; Gilardini Montani MS; Santarelli R; D'Orazi G; Faggioni A; Cirone M
    J Exp Clin Cancer Res; 2017 Nov; 36(1):167. PubMed ID: 29179721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inactivation by ROS-JNK-p53 pathway plays an essential role in psedolaric acid B induced autophagy-dependent senescence in murine fibrosarcoma L929 cells.
    Qi M; Zhou H; Fan S; Li Z; Yao G; Tashiro S; Onodera S; Xia M; Ikejima T
    Eur J Pharmacol; 2013 Sep; 715(1-3):76-88. PubMed ID: 23810968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vicious cycle between ferritinophagy and ROS production triggered EMT inhibition of gastric cancer cells was through p53/AKT/mTor pathway.
    Xu Z; Feng J; Li Y; Guan D; Chen H; Zhai X; Zhang L; Li C; Li C
    Chem Biol Interact; 2020 Sep; 328():109196. PubMed ID: 32687844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O
    Cordani M; Butera G; Dando I; Torrens-Mas M; Butturini E; Pacchiana R; Oppici E; Cavallini C; Gasperini S; Tamassia N; Nadal-Serrano M; Coan M; Rossi D; Gaidano G; Caraglia M; Mariotto S; Spizzo R; Roca P; Oliver J; Scupoli MT; Donadelli M
    Br J Cancer; 2018 Oct; 119(8):994-1008. PubMed ID: 30318520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berberine Inhibits Cell Proliferation by Interfering with Wild-Type and Mutant P53 in Human Glioma Cells.
    Liu Z; Chen Y; Gao H; Xu W; Zhang C; Lai J; Liu X; Sun Y; Huang H
    Onco Targets Ther; 2020; 13():12151-12162. PubMed ID: 33262612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBA Preferentially Impairs Cell Survival of Glioblastomas Carrying mutp53 by Reducing Its Expression Level, Stabilizing wtp53, Downregulating the Mevalonate Kinase and Dysregulating UPR.
    Romeo MA; Gilardini Montani MS; Benedetti R; Garufi A; D'Orazi G; Cirone M
    Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32290231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
    D'Orazi G; Garufi A; Cirone M
    IUBMB Life; 2020 Aug; 72(8):1634-1639. PubMed ID: 32593231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.